WO2021224455A1 - Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity - Google Patents

Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity Download PDF

Info

Publication number
WO2021224455A1
WO2021224455A1 PCT/EP2021/062135 EP2021062135W WO2021224455A1 WO 2021224455 A1 WO2021224455 A1 WO 2021224455A1 EP 2021062135 W EP2021062135 W EP 2021062135W WO 2021224455 A1 WO2021224455 A1 WO 2021224455A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
species
weight
strengthening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/062135
Other languages
French (fr)
Inventor
Saad Harti
Jiawei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Legacy Healthcare Switzerland SA
Original Assignee
Legacy Healthcare Switzerland SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legacy Healthcare Switzerland SA filed Critical Legacy Healthcare Switzerland SA
Priority to JP2022567246A priority Critical patent/JP2023529062A/en
Priority to AU2021267004A priority patent/AU2021267004A1/en
Priority to BR112022021695A priority patent/BR112022021695A2/en
Priority to CN202180033443.9A priority patent/CN115666525A/en
Priority to EP21723282.6A priority patent/EP4146169A1/en
Priority to US17/922,884 priority patent/US20230270812A1/en
Priority to KR1020227041721A priority patent/KR20230007451A/en
Priority to MX2022013868A priority patent/MX2022013868A/en
Priority to CA3177105A priority patent/CA3177105A1/en
Publication of WO2021224455A1 publication Critical patent/WO2021224455A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/577Malvaceae (Mallow family)
    • A61K36/5777Theobroma, e.g. cocao or cocoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/77Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962Allium, e.g. garden onion, leek, garlic or chives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention concerns compositions used in a method for strengthening the immune system of human and animal to acquire pan-immunity.
  • compositions comprising the ingredients mentioned hereafter enabled significant improvement of health condition related to strengthened and good function of immune system.
  • the present invention is a method to improve the general immunologic status, which is different from an antibiotic invention, which needs test against certain pathogens.
  • the composition in the present invention has a function to ameliorate immune system as revealed at two scientifically proved levels: 1. increased volunteer wheel running activity (VWRA); and 2. down-regulation of il- 8, an indirect method to measure immune-improving or immunomodulatory bio- activity (see descriptions below).
  • tyrosine hydroxylase is key for dopamine production because dopamine is derived from a two-step process starting with the hydroxylation of L-tyrosine by the enzyme TH (Sato et al. (2010), Fermented soymilk increases voluntary wheel running activity and sexual behavior in male rats. Appl. Physiol. Nutr. Metab. 35: 749 754; Wagar et al. (2009), Immunomodulatory Properties of Fermented Soy and Dairy Milks Prepared with Lactic Acid Bacteria. JOURNAL OF FOOD SCIENCE, Vol. 74, Nr. 8).
  • Immunomodulatory bioactivity of a variety of bioactive components can be assessed on the pro-inflammatory response of intestinal epithelial cells (IEC)following Tumor Necrosis Factor a (TNFa) treatment, by measuring the impact on IL-8 production.
  • IEC intestinal epithelial cells
  • TNFa Tumor Necrosis Factor a
  • down-regulation of IL-8 production has been observed (Wagar et al above), finding consistent with the observations for the immunity-improving bioactivity of the composition according to the present application, i.e. down-regulation of IL-8 production in TNFa-challenged human endothelial cells (see below “Example 2: Immunomodulatory/anti-inflammatory effect”).
  • the immunomodulatory effect of the composition according to the invention is shown in the immunosuppressed mouse model by increased voluntary wheel running capacity.
  • the animal model used in the application is a mouse model of fatigue induced by peripheral irradiation. It has been documented that irradiation can cause generalized immunosuppression, mainly due to lymphocyte apoptosis and dysfunction of immune regulation (McFarland et al. (2012), Regulatory T Cells in g Irradiation-Induced Immune Suppression. PLoS ONE 7(6): e39092. doi: 10.1371 /journal. pone.0039092).
  • composition according to the invention comprising the ingredients mentioned hereafter, provides with a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.
  • cytokine storm a dangerous overreaction of the immune system.
  • composition according to the invention on its immunity-improving / immunomodulatory/anti-inflammatory effect via down-regulation of TNF alpha- induced expression of pro-inflammatory molecules: Interleukin 8, ICAM-1 and E- selectin, is also presented hereafter in the Experimental Part in Tables 2-4.
  • the present invention concerns a composition to be used for strengthening the immunity system containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the extract of Paullinia species and/or the extract of Theobroma species can be atomized or not.
  • the said composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract of Paullinia species and from 0.05% to 5.0% by weight of an extract of Theobroma species, based on the total weight of the four active ingredients.
  • the said composition contains from 60% to 70% by weight of an extract of Allium cepa, from 7% to 12% by weight of an extract of Citrus limon, from 0.08% to 0.20% by weight of an extract of Paullinia cupana and from 0.06% to 0.18% by weight of an extract of Theobroma cacao, based on the total weight of the four active ingredients.
  • the said composition contains as excipients from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition This composition is to be used to acquire pan-immunity.
  • the composition is to be used to prevent and to treat infectious and other diseases with immunological components, such as viral infections and/or auto-immune diseases, including eliminating cancer cells.
  • immunological components such as viral infections and/or auto-immune diseases, including eliminating cancer cells.
  • this composition is to be used as adjuvant potentiator in various therapies or treatments.
  • This composition is to be administrated by parenteral route, non-parenteral route, oral route or local or topical routes, or in combination thereof.
  • a composition comprising the ingredients mentioned hereafter was administered topically to human subjects with abnormal conditions in terms of inflammation. It was observed that, the composition significantly improved the inflammatory skin condition thanks to the anti-inflammatory function of the composition.
  • the present invention proposes a method for the improvement/strengthening of the immune system; comprising the administration by oral, parenteral, topical application, or local injection, and/or as adjuvant potentiator in various therapies/treatments, or in combination, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the present invention concerns a method for strengthening immunity system; comprising the administration by oral route, or parenteral route, or topical application, or injection, or a combination thereof, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the preferred composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to
  • the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
  • compositions are used not only as conventional oral composition, composition for injection (local or systemic), but also as an adjuvant potentiator in therapies/treatments for strengthening the immunity system to acquire pan-immunity.
  • the compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the weight of the four active ingredients.
  • the compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
  • extract of Allium species refers particularly to extracts and native extracts obtained from all species of the genus Allium (family Liliaceae), and especially Allium cepa.
  • the term genus citrus refers particularly to the family Rutaceae, especially Citrus limon.
  • extract (atomized or not) of Paullinia species refers particularly to extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae), especially Paullinia cupana (Guarana).
  • extract (atomized or not) of Theobroma species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Theobroma (family Malvaceae), and especially Theobroma cacao.
  • compositions used according to the invention are: those containing approximately 66% by weight of an extract of Allium cepa, approximately 9% by weight of an extract of Citrus limon, approximately 0.11 % by weight of an extract (atomized or not) of Paullinia cupana and approximately 0.11 % by weight of an extract (atomized or not) of Theobroma cacao, based on the total weight of the four active ingredients.
  • the composition is chronically administered in a mixture containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • the composition is administered daily during a period of several months or longer with a composition containing as active ingredients an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
  • compositions obtained according to the invention doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned.
  • Pharmaceutical compositions normally contain from 0.4 to 1000 mg, preferably from 2 to 400 mg, of active ingredients as defined above, in the form of dry extract or liquid solution.
  • the composition can be orally administered in human, twice daily, with 5 ml each intake.
  • the present invention also concerns a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in strengthening the immunity system in order to acquire pan-immunity, by oral, parenteral, other above-mentioned routes, and/or as adjuvant potentiator in various therapies/treatments, or in combination thereof.
  • the composition for use in strengthening the immunity system in order to acquire pan-immunity contains an extract of Allium species, an extract of Citrus species and an extract (atomized or not) of Paullinia species and an extract (atomized or not) of Theobroma species.
  • the composition for use in strengthening the immunity system in order to acquire pan-immunity contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • Example 4 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition: - an extract of Allium cepa (containing quercetin): 45.50 %
  • Example 6 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • Example 8 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
  • excipients used in the above examples are from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weigh of glycerine, based on the total weight of the composition.
  • mice have surprisingly shown a strengthening of their immunity system significantly demonstrated according to a mode of evidence known in the art, as explained above, measured by their increased wheel running capacity in comparison with the level of their immunity system before intake of the composition.
  • composition according to the present invention is capable of positively influencing and strengthening the immunity system.
  • VWRA Running Activity
  • composition group (“Drug”) was 17% greater than Placebo group. “The composition” group mice returned to daily running distance baseline after 7 days; placebo mice returned to baseline running distance 12 days after irradiation.
  • Example 2 Immunity-improving/Immunomodulatory/anti-inflammatory effect The study outcome summary is presented below in Tables 2-4.
  • composition within the ranges in the examples 1 to 10 containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, was used to perform the study on its immunity-improving/immunomodulatory/anti-inflammatory effect via down- regulation of TNF alpha-induced expression of pro-inflammatory molecules: Interleukin-8, ICAM-1 and E-selectin, as summarized in Table 2-4.
  • a composition according to the invention enabled modulation of the over-reaction of immune response through anti-inflammation. Consequently, the composition improved health condition as a result of good functioning of the strengthened immune system.
  • a composition according to the invention provides a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention concerns a composition for strengthening the immunity system to acquire pan-immunity, for the prevention and treatments of infectious and other diseases with immunological components, including eliminating cancer cells. According to the invention the administration of the composition can be by oral, parenteral or non-parenteral routes, local injection, topical application, or in combinations thereof, and the administration of the composition as adjuvant potentiator in various therapies/treatments uses the aforenamed routes. The composition contains, as active ingredients, an extract of Allium species and an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.

Description

COMPOSITION TO BE USED FOR STRENGTHENING THE IMMUNE SYSTEM IN HUMAN AND ANIMAL TO ACQUIRE PAN-IMMUNITY
TECHNICAL FIELD
The invention concerns compositions used in a method for strengthening the immune system of human and animal to acquire pan-immunity.
BACKGROUND
Facing the wide variety of disease-causing pathogens, the immune system is essential to our survival. Immunological impairment has devastating consequences. Good and healthy immune system orchestrates a potent defense that consists of affecting the functions of immune cells or affecting antibody secretion to control the infection to maintain immune homeostasis. This is possible through direct or indirect involvement of molecular and cellular inflammatory processes. It is therefore of great importance to enhance the immune system's protective actions against pathogenic agents and tumor cells and to control its actions in order not to develop autoimmune diseases and other disorders with immunological components.
The invention concerns a composition used in a method for strengthening the immune systems of human and animal to acquire pan-immunity. The purpose of the method is to treat and prevent all types of pathogen infection (e.g. bacteria, viruses, fungi, prion and ectoparasites, as well as protozoan infection), and all immune-related diseases that are due to dysfunction of immune system, including eliminating cancer cells. The diseases can be spread through, but not limited to skin contact, the transfer of bodily fluids, contact with faces, ingesting contaminated food or water, inhaling airborne particles or droplets, touching an object carrying the pathogen, etc. Particularly, the method deals with all symptoms/syndromes related the above-mentioned conditions, as well as the post-infection and post-treatment symptoms/syndromes, such as Post- Treatment Lyme Disease Syndrome.
Sometimes there is no visible symptom following infection. Some examples of the symptoms following infection include, but not limited to: fever, chills, cold-related symptoms (e.g. runny nose, sneezing, and congestion), Influenza-related symptoms (e.g. muscle pain, cough, congestion, headache, fatigue), strep throat symptoms (e.g. sore throat, swollen lymph nodes), urinary tract infection symptoms (e.g. pelvic pain, urinating pain and blood in the urine, back pain due to kidney infection), infectious cellulitis (e.g. swollen red and sensitive ski), gastroenteritis (e.g. diarrheal, cramps, vomiting), acute pneumonia (e.g. cough with expectoration of phlegm or pus), severe acute respiratory syndrome, otitis media (e.g. ear pain and fluid leaking out of ear or hearing loss), sexually transmitted diseases, etc...
Our study showed that a composition comprising the ingredients mentioned hereafter enabled significant improvement of health condition related to strengthened and good function of immune system. However, the present invention is a method to improve the general immunologic status, which is different from an antibiotic invention, which needs test against certain pathogens. The composition in the present invention has a function to ameliorate immune system as revealed at two scientifically proved levels: 1. increased volunteer wheel running activity (VWRA); and 2. down-regulation of il- 8, an indirect method to measure immune-improving or immunomodulatory bio- activity (see descriptions below).
Based on state-of-the-art scientific knowledge known to those skilled in the art, the experimental data in the present application show evidence that the composition has beneficial effects on immunologic status. Such beneficial effects are shown by the capacity of “voluntary wheel -running” in the mouse model, as illustrated hereafter.
Scientific evidence exists showing an association between improved immunity and increased voluntary wheel running activity in rodent (as illustrated below).
Earlier studies pinpointed numerous genes expression patterns annotated to the immune process, immune response, and immune system organ morphology, as well as cytokine interactions were differentially expressed between high voluntary running capacity mice and control mice (Zhang et al.Brain region-dependent gene networks associated with selective breeding for increased voluntary wheel-running behavior. PLOS ONE, August 2, 2018 - https://doi.org/10.1371/journal.pone.0201773).
Other studies demonstrated that intake of certain natural immunity-improving components, such as those found in fermented soymilk (FSM) increased voluntary wheel running activity in rodent. Further analyses revealed that following FSM administration, there was an increased protein production of tyrosine hydroxylase (TH), suggesting the involvement of dopamine signaling. Indeed, tyrosine hydroxylase is key for dopamine production because dopamine is derived from a two-step process starting with the hydroxylation of L-tyrosine by the enzyme TH (Sato et al. (2010), Fermented soymilk increases voluntary wheel running activity and sexual behavior in male rats. Appl. Physiol. Nutr. Metab. 35: 749 754; Wagar et al. (2009), Immunomodulatory Properties of Fermented Soy and Dairy Milks Prepared with Lactic Acid Bacteria. JOURNAL OF FOOD SCIENCE, Vol. 74, Nr. 8).
Dopamine is well recognized as a neurotransmitter in the brain. It regulates, as a broad immunomodulator, critical functions in a variety of peripheral systems, particularly regulating immune function. Many immune cells (e.g. T-lymphocytes) express dopamine receptors, enabling them to actively respond centrally and peripherally to dopamine. Hence, dopaminergic immunoregulation is an important part of immune function. Furthermore, the bone marrow microenvironment is critical in the maintenance of hematopoietic stem cells (HSCs), from which immune cells are derived through hematopoiesis. Dopamine signaling has been shown to regulate HSCs development and function. Meanwhile, dopamine regulates a variety of immune functions including cytokine secretion (Matt et al. Where Is Dopamine and how do Immune Cells See it? : Dopamine-Mediated Immune Cell Function in Health and Disease. Journal ofNeuroimmune Pharmacology, 11 May 2019).
Immunomodulatory bioactivity of a variety of bioactive components (e.g. those found in fermented soy beverage) can be assessed on the pro-inflammatory response of intestinal epithelial cells (IEC)following Tumor Necrosis Factor a (TNFa) treatment, by measuring the impact on IL-8 production. Regarding the immunity-improving fermented soy beverage and milk blend, down-regulation of IL-8 production has been observed (Wagar et al above), finding consistent with the observations for the immunity-improving bioactivity of the composition according to the present application, i.e. down-regulation of IL-8 production in TNFa-challenged human endothelial cells (see below “Example 2: Immunomodulatory/anti-inflammatory effect”). On the other hand, the immunomodulatory effect of the composition according to the invention is shown in the immunosuppressed mouse model by increased voluntary wheel running capacity.
The animal model used in the application is a mouse model of fatigue induced by peripheral irradiation. It has been documented that irradiation can cause generalized immunosuppression, mainly due to lymphocyte apoptosis and dysfunction of immune regulation (McFarland et al. (2012), Regulatory T Cells in g Irradiation-Induced Immune Suppression. PLoS ONE 7(6): e39092. doi: 10.1371 /journal. pone.0039092).
Under such circumstances, without treatment, as shown by the experimental results in the present application (see Table 1 and Figure 1) the Voluntary Wheel Running Activity (VWRA) of mice was greatly reduced. However, the intake of the composition according to the invention improved such a wheel running capacity (both running distance and speed, see Table 1 and Figures 2, 3, 4) post-irradiation, showing an amelioration of immunologic status, which is associated, as explained above, with the increased voluntary wheel running capacity of mice.
The study outcome summary is presented hereafter in the Experimental Part in Table 1 and in Figures 1 - 6.
Thus, a composition according to the invention, comprising the ingredients mentioned hereafter, provides with a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.
A composition comprising the ingredients mentioned hereafter was administered orally to mice with immune deficiency conditions, in a placebo-controlled experiment. It was observed that, compared to placebo-treated mice, the composition significantly improved their health status thanks to reestablishment of good function of the strengthened immune system, demonstrated and measured by significantly increased wheel running capacity.
Activation of the immune system by infection, injury, or trauma leads to the release of pro-inflammatory cytokines and other immune factors, in some cases, even resulting in “cytokine storm” (a dangerous overreaction of the immune system). These cytokines orchestrate local and systemic riotous immune responses and mediate various pathologic conditions.
A study of the composition according to the invention, on its immunity-improving / immunomodulatory/anti-inflammatory effect via down-regulation of TNF alpha- induced expression of pro-inflammatory molecules: Interleukin 8, ICAM-1 and E- selectin, is also presented hereafter in the Experimental Part in Tables 2-4.
SUMMARY The present invention concerns a composition to be used for strengthening the immunity system containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species. The extract of Paullinia species and/or the extract of Theobroma species can be atomized or not. According to another embodiment of the present invention, the said composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract of Paullinia species and from 0.05% to 5.0% by weight of an extract of Theobroma species, based on the total weight of the four active ingredients. According to a further embodiment of the present invention, the said composition contains from 60% to 70% by weight of an extract of Allium cepa, from 7% to 12% by weight of an extract of Citrus limon, from 0.08% to 0.20% by weight of an extract of Paullinia cupana and from 0.06% to 0.18% by weight of an extract of Theobroma cacao, based on the total weight of the four active ingredients. Also, according to an embodiment of the present invention, the said composition contains as excipients from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition This composition is to be used to acquire pan-immunity.
According to another embodiment, the composition is to be used to prevent and to treat infectious and other diseases with immunological components, such as viral infections and/or auto-immune diseases, including eliminating cancer cells.
Also, according to a further embodiment, this composition is to be used as adjuvant potentiator in various therapies or treatments. This composition is to be administrated by parenteral route, non-parenteral route, oral route or local or topical routes, or in combination thereof.
DETAILED DESCRIPTION It has been discovered that the administration by oral route, or parenteral route, or local injection, or a combination thereof, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, has a novel and previously unknown effect for strengthening the immune system in human and animal in order to acquire pan-immunity.
A composition comprising the ingredients mentioned hereafter was administered topically to human subjects with abnormal conditions in terms of inflammation. It was observed that, the composition significantly improved the inflammatory skin condition thanks to the anti-inflammatory function of the composition. The present invention proposes a method for the improvement/strengthening of the immune system; comprising the administration by oral, parenteral, topical application, or local injection, and/or as adjuvant potentiator in various therapies/treatments, or in combination, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
In particular, the present invention concerns a method for strengthening immunity system; comprising the administration by oral route, or parenteral route, or topical application, or injection, or a combination thereof, of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species. Among the methods for strengthening immunity system to acquire pan-immunity, according to the invention, those which are of more particular interest are the methods in which the preferred composition contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to
5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients. According to an embodiment, the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
Among the methods for strengthening the immunity system, those which are the more preferred interest are the methods in which the compositions are used not only as conventional oral composition, composition for injection (local or systemic), but also as an adjuvant potentiator in therapies/treatments for strengthening the immunity system to acquire pan-immunity. The compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the weight of the four active ingredients. According to an embodiment, the compositions contain from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients. According to an embodiment, the composition comprises from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, from 1.0% to 8.0% by weight of Sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
The term extract of Allium species refers particularly to extracts and native extracts obtained from all species of the genus Allium (family Liliaceae), and especially Allium cepa.
The term genus citrus refers particularly to the family Rutaceae, especially Citrus limon.
The term extract (atomized or not) of Paullinia species refers particularly to extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae), especially Paullinia cupana (Guarana). The term extract (atomized or not) of Theobroma species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Theobroma (family Malvaceae), and especially Theobroma cacao.
The most preferred compositions used according to the invention are: those containing approximately 66% by weight of an extract of Allium cepa, approximately 9% by weight of an extract of Citrus limon, approximately 0.11 % by weight of an extract (atomized or not) of Paullinia cupana and approximately 0.11 % by weight of an extract (atomized or not) of Theobroma cacao, based on the total weight of the four active ingredients. According to the invention, the composition is chronically administered in a mixture containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species. According to an embodiment of the invention the composition is administered daily during a period of several months or longer with a composition containing as active ingredients an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
In order to obtain a measurable effect on the strengthening of the immunity system to acquire pan-immunity, it is necessary to perform the administration of the compositions chronically. When using the compositions obtained according to the invention, doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned. Pharmaceutical compositions normally contain from 0.4 to 1000 mg, preferably from 2 to 400 mg, of active ingredients as defined above, in the form of dry extract or liquid solution. For example, the composition can be orally administered in human, twice daily, with 5 ml each intake. The present invention also concerns a composition containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species for use in strengthening the immunity system in order to acquire pan-immunity, by oral, parenteral, other above-mentioned routes, and/or as adjuvant potentiator in various therapies/treatments, or in combination thereof. According to an embodiment of the invention the composition for use in strengthening the immunity system in order to acquire pan-immunity contains an extract of Allium species, an extract of Citrus species and an extract (atomized or not) of Paullinia species and an extract (atomized or not) of Theobroma species. According to a further embodiment of the invention the composition for use in strengthening the immunity system in order to acquire pan-immunity, contains from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract (atomized or not) of Paullinia species and from 0.05% to 5.0% by weight of an extract (atomized or not) of Theobroma species, based on the total weight of the four active ingredients.
EXAMPLES OF COMPOSITIONS / TREATMENTS Example 1 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa (containing quercetin): 71 %
- an extract of Citrus limon: 1.7 %
- an atomised extract of Paullinia cupana: 4.5 % - an atomised extract of Theobroma cacao: 4.8 %
Example 2
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa (containing quercetin): 60.50 % - an extract of Citrus limon: 5.25 %
- an atomised extract of Paullinia cupana: 2.5 %
- an atomised extract of Theobroma cacao: 2.3 %
Example 3
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa (containing quercetin): 52.50 %
- an extract of Citrus limon: 6.20 %
- an atomised extract of Paullinia cupana: 1 %
- an atomised extract of Theobroma cacao: 1 %
Example 4 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa (containing quercetin): 48.50 %
- an extract of Citrus limon: 20.5 % - an atomised extract of Paullinia cupana: 1.5 %
- an atomised extract of Theobroma cacao: 1.35%
Example 5
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition: - an extract of Allium cepa (containing quercetin): 45.50 %
- an extract of Citrus limon: 20 %
- an atomised extract of pulverized Paullinia cupana: 0.75 %
- an atomised extract of Theobroma cacao: 0.65%
Example 6 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa (containing quercetin): 31.50 %
- an extract of Citrus limon: 18 %
- an atomised extract of Paullinia cupana: 0.15 % - an atomised extract of pulverized Theobroma cacao: 0.18%
Example 7
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of a species of the genus Allium belonging to the family Liliaceae other than Allium cepa: 30.50 %
- an extract of Citrus limon: 3.20 %
- an extract of Paullinia cupana: 0.06 %
- an atomised extract of Theobroma cacao: 0.05%
Example 8 The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa: 30.50 %
- an extract of Citrus limon: 3.20 % - an atomised extract of Paullinia cupana: 0.06 %
- an extract of Theobroma cacao: 0.05%
Example 9
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa: 35.50 %
- an extract of Citrus limon: 3.80 %
- an atomised extract of Paullinia cupana: 0.03 %
- an atomised extract of Theobroma cacao: 0.03% Example 10
The mice have received, every day by oral route, a treatment with a composition having, independently from the excipients, the following composition:
- an extract of Allium cepa 36.45 %
- an extract of Citrus limon: 10% - an extract of Paullinia cupana: 2.5 %
- an hydroalcoholic extract of Theobroma cacao : 1.35%
The excipients used in the above examples are from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weigh of glycerine, based on the total weight of the composition.
EXPERIMENTAL RESULTS
The results are obtained by using the above compositions within the ranges in the examples 1 to 10. For all the above compositions, the tests performed on mice have surprisingly shown a strengthening of their immunity system significantly demonstrated according to a mode of evidence known in the art, as explained above, measured by their increased wheel running capacity in comparison with the level of their immunity system before intake of the composition.
This indicates that the composition according to the present invention is capable of positively influencing and strengthening the immunity system.
Our studies have shown that a composition comprising the ingredients mentioned hereafter enabled significant improvement of health conditions related to strengthened and good function of immune system. Example 1: Wheel running activity:
The study outcome summary is presented below in Table 1 and Figures 1 - 6.
Table 1. Outcome of study on the composition to improve immunologic status in a mouse model, that is shown by enhanced Voluntary Wheel
Running Activity (VWRA)
Figure imgf000013_0001
Figure 1. VWRA of placebo-mice was greatly reduced, and reached the lowest running distance at day 3 post-irradiation. Mice recovered gradually over the next several days, returning to the initial running distance measured in the pre-irradiation period.
Figure 2. Average cumulative distance run during post-irradiation by “the composition” group (“Drug”) was 17% greater than Placebo group. “The composition” group mice returned to daily running distance baseline after 7 days; placebo mice returned to baseline running distance 12 days after irradiation.
Figure 3. As in the described model, a decrease in voluntary wheel speed is most pronounced during the late hours of the active phase (i.e. dark cycle). The average post-irradiation running speed was systematically greater in the “the composition” group (“Drug”) versus placebo group, in every section of the active phase.
Figure 4. As in the described model, a decrease in voluntary wheel distance is most pronounced during the late hours of the active phase (i.e. dark cycle). The average post-irradiation running distance was systematically greater in the “the composition” group (“Drug”) versus placebo group, in every section of the active phase.
Figure 5. Both “the composition” and Placebo were given in a 1% saccharin solution. Volume of solution consumed by mice in “the composition” group (“Drug”) was less than mice in Placebo group, before and after irradiation.
Figure 6. The mean group body weight showed that there was no difference in body weight between mice in Placebo group and mice in “the composition” group (“Drug”).
Example 2: Immunity-improving/Immunomodulatory/anti-inflammatory effect The study outcome summary is presented below in Tables 2-4.
The composition within the ranges in the examples 1 to 10, containing as active ingredient an extract of Allium species, an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species, was used to perform the study on its immunity-improving/immunomodulatory/anti-inflammatory effect via down- regulation of TNF alpha-induced expression of pro-inflammatory molecules: Interleukin-8, ICAM-1 and E-selectin, as summarized in Table 2-4.
Table 2. The effects of “composition” on the expression of cytokine Interleukin-8 (IL-8) by endothelial cells (HUVECs)
Figure imgf000015_0001
* specific Antibody Bound per Cell
Table 3. The effects of “composition” on the expression of adhesion molecule E- selectin/ELAM-1 (CD62E) on the surface of endothelial cells (HUVECs)
Figure imgf000015_0002
* specific Antibody Bound per Cell
Table 4. The effects of “composition” on the expression of adhesion molecule ICAM-1 (CD54) on the surface of endothelial cells (HUVECs)
Figure imgf000016_0001
Figure imgf000016_0002
* specific Antibody Bound per Cell
Hence, the above study shows that a composition according to the invention enabled modulation of the over-reaction of immune response through anti-inflammation. Consequently, the composition improved health condition as a result of good functioning of the strengthened immune system. Thus, a composition according to the invention provides a method for strengthening the immune system for good immune functions and finally acquire pan-immunity.

Claims

1. A composition to be used for strengthening the immunity system in human and animal containing as active ingredients an extract of Allium species and an extract of Citrus species and an extract of Paullinia species and an extract of Theobroma species.
2. A composition for strengthening the immunity system according to claim 1, wherein the extract of Paullinia species and/or the extract of Theobroma species are atomized or not.
3. A composition for strengthening the immunity system according to claim 1 or 2, said composition containing from 20% to 80% by weight of an extract of Allium species, from 1.5% to 20% by weight of an extract of Citrus species, from 0.05% to 5.0% by weight of an extract of Paullinia species and from 0.05% to 5.0% by weight of an extract of Theobroma species, based on the total weight of the four active ingredients.
4. A composition for strengthening the immunity system according to any one of claims 1 to 3, said composition containing from 60% to 70% by weight of an extract of Allium cepa, from 7% to 12% by weight of an extract of Citrus limon, from 0.08% to 0.20% by weight of an extract of Paullinia cupana and from 0.06% to 0.18% by weight of an extract of Theobroma cacao, based on the total weight of the four active ingredients.
5. A composition for strengthening the immunity system according to any one of claims 1 to 4, said composition containing from 32% to 45% by weight of an extract of Allium cepa, 6 to 12% of an extract of Citrus limon, 2 to 3% of an extract of Paullinia cupana, 0.25 to 3,2 % of an hydroalcoholic extract of Theobroma cacao.
6. A composition for strengthening the immunity system according to any one of claims 1 to 5, further containing as excipients from 1.0% to 8.0% by weight of sodium chloride and from 10% to 40% by weight of glycerine, based on the total weight of the composition.
7. A composition for strengthening the immunity system according to any one of claims 1 to 5, to be used to acquire pan-immunity.
8. A composition for strengthening the immunity system according to any one of claims 1 to 7, to be used to acquire pan-immunity, to prevent and to treat infectious and other diseases with immunological components, including eliminating cancer cells.
9. A composition for strengthening the immunity system according to any one of claims 1 to 7, to be used as adjuvant potentiator in various therapies or treatments.
10. A composition for strengthening the immunity system according to any one of claims 1 to 9, in an appropriate form to be administrated by parenteral, non-parenteral, oral, local, topical routes or in combinations thereof.
PCT/EP2021/062135 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity Ceased WO2021224455A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2022567246A JP2023529062A (en) 2020-05-07 2021-05-07 Compositions used to strengthen the immune system to achieve pan-immunity in humans and animals
AU2021267004A AU2021267004A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
BR112022021695A BR112022021695A2 (en) 2020-05-07 2021-05-07 COMPOSITION TO BE USED TO STRENGTHEN THE IMMUNE SYSTEM IN HUMANS AND ANIMALS TO ACQUIRE PAN-IMMUNITY
CN202180033443.9A CN115666525A (en) 2020-05-07 2021-05-07 Compositions for enhancing the immune system of humans and animals to obtain various immunities
EP21723282.6A EP4146169A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
US17/922,884 US20230270812A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
KR1020227041721A KR20230007451A (en) 2020-05-07 2021-05-07 Compositions used for enhancing the immune system of humans and animals to obtain pan-immunity
MX2022013868A MX2022013868A (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity.
CA3177105A CA3177105A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2004533A FR3109881B1 (en) 2020-05-07 2020-05-07 PROCESS FOR IMPROVING THE IMMUN SYSTEM TO ACQUIRE PAN-IMMUNITY
FRFR2004533 2020-05-07

Publications (1)

Publication Number Publication Date
WO2021224455A1 true WO2021224455A1 (en) 2021-11-11

Family

ID=72644307

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/062135 Ceased WO2021224455A1 (en) 2020-05-07 2021-05-07 Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity

Country Status (11)

Country Link
US (1) US20230270812A1 (en)
EP (1) EP4146169A1 (en)
JP (1) JP2023529062A (en)
KR (1) KR20230007451A (en)
CN (1) CN115666525A (en)
AU (1) AU2021267004A1 (en)
BR (1) BR112022021695A2 (en)
CA (1) CA3177105A1 (en)
FR (1) FR3109881B1 (en)
MX (1) MX2022013868A (en)
WO (1) WO2021224455A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss
WO2024236145A1 (en) * 2023-05-17 2024-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912310A1 (en) * 2007-02-13 2008-08-15 Kasan Sarl Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate
WO2012140013A2 (en) * 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
US20130323334A1 (en) * 2011-02-23 2013-12-05 Legacy Healthcare Ltd. Use Of Compositions For Preventing Chemotherapy And Radiotherapy Induced Alopecia (CRIA), Reducing CRIA Impact And Improving The Appearance Of Hair Re-Growth After CRIA
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity
US20190314441A1 (en) * 2013-11-08 2019-10-17 Legacy Healthcare Ltd. Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020719A2 (en) * 2011-08-09 2013-02-14 Legacy Healthcare Holding Ltd New use of compositions to delay the onset of the catagen phase of the hair
EP2862598A1 (en) * 2013-10-16 2015-04-22 Legacy Healthcare Holding Ltd. Use of a composition for the pigmentation of hair and hairs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912310A1 (en) * 2007-02-13 2008-08-15 Kasan Sarl Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate
US20130323334A1 (en) * 2011-02-23 2013-12-05 Legacy Healthcare Ltd. Use Of Compositions For Preventing Chemotherapy And Radiotherapy Induced Alopecia (CRIA), Reducing CRIA Impact And Improving The Appearance Of Hair Re-Growth After CRIA
WO2012140013A2 (en) * 2011-04-11 2012-10-18 Legacy Healthcare Holding Ltd New use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions and collagen remodeling.
US20190314441A1 (en) * 2013-11-08 2019-10-17 Legacy Healthcare Ltd. Method For The Management Of Cancer And Cancer Treatment-Related Comorbidities
WO2017186954A1 (en) * 2016-04-28 2017-11-02 Legacy Healthcare Ltd Method for the improvement of speed and endurance capacity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KANG DANBEE ET AL: "Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)", SUPPORTIVE CARE IN CANCER, SPRINGER VERLAG, BERLIN, DE, vol. 28, no. 4, 23 July 2019 (2019-07-23), pages 1829 - 1837, XP037030508, ISSN: 0941-4355, [retrieved on 20190723], DOI: 10.1007/S00520-019-04982-Z *
MATT ET AL.: "Where Is Dopamine and how do Immune Cells See it?:Dopamine-Mediated Immune Cell Function in Health and Disease", JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 11 May 2019 (2019-05-11)
MCFARLAND ET AL.: "Regulatory T Cells in y Irradiation-Induced Immune Suppression", PLOS ONE, vol. 7, no. 6, 2012, pages e39092
SATO ET AL.: "Fermented soymilk increases voluntary wheel running activity and sexual behavior in male rats", APPL. PHYSIOL. NUTR. METAB., vol. 35, 2010, pages 749 - 754
See also references of EP4146169A1
WAGAR ET AL.: "Immunomodulatory Properties of Fermented Soy and Dairy Milks Prepared with Lactic Acid Bacteria", JOURNAL OF FOOD SCIENCE, vol. 74, no. 8, 2009, XP055318149, DOI: 10.1111/j.1750-3841.2009.01308.x
ZHANG ET AL.: "Brain region-dependent gene networks associated with selective breeding for increased voluntary wheel-running behavior", PLOS ONE, 2 August 2018 (2018-08-02), Retrieved from the Internet <URL:https:lldoi.orgl]O.137]ljournalpone.0201773>

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11819530B1 (en) 2023-05-17 2023-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss
WO2024236145A1 (en) * 2023-05-17 2024-11-21 Legacy Healthcare (Switzerland) Sa Long term treatment of hair loss

Also Published As

Publication number Publication date
FR3109881A1 (en) 2021-11-12
MX2022013868A (en) 2023-02-09
US20230270812A1 (en) 2023-08-31
BR112022021695A2 (en) 2022-12-20
FR3109881B1 (en) 2022-10-21
CN115666525A (en) 2023-01-31
AU2021267004A1 (en) 2022-12-15
KR20230007451A (en) 2023-01-12
EP4146169A1 (en) 2023-03-15
CA3177105A1 (en) 2021-11-11
JP2023529062A (en) 2023-07-07

Similar Documents

Publication Publication Date Title
CN116490198A (en) Aloe-based compositions comprising polysaccharides and polyphenols for regulating immune homeostasis
Bao et al. Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis
US20230270812A1 (en) Composition to be used for strengthening the immune system in human and animal to acquire pan-immunity
CN108420826B (en) Use of Lycium barbarum polysaccharide in preparing medicine for treating or relieving depression and pharmaceutical composition containing the same
Omer et al. A review on the antiviral activity of functional foods against COVID-19 and viral respiratory tract infections
US20110160136A1 (en) Polyphenols for the treatment of cartilage disorders
KR101740028B1 (en) Composition for preventing, improving, or treating arthritis comprising Achyranthis Japonicae Radix and Scutellariae Radix or Achyranthis Japonicae Radix, Scutellariae Radix and Acanthopanacis Cortex
Ahmed et al. Navel orange peel ethanolic extract and naringin ameliorate CFA-induced arthritis in Wistar rats through their modulatory effects on Th1/Th2/Th17 cytokines and oxidative stress
CN103656048B (en) Medicine being used for the treatment of mammitis of cow and preparation method thereof
US8609155B2 (en) Dietary supplement stimulating the male sexual function
CN111067971A (en) Traditional Chinese medicine composition for treating paronychia and using method thereof
Bilir et al. Evaluation of the effect of Anatolian propolis on Covid-19 in healthcare professionals: Effect of Anatolian propolis on Covid-19
KR20070100560A (en) Functional drink for strengthening immunity and manufacturing method thereof
Al-Hasnawi et al. Effect of Aloe vera extract on some parameter complete blood count and liver functions induced by azathioprine in changes male rats
CN103142943B (en) Traditional Chinese medicine composite with immune function and used for treating mastitis of cows
KR102087338B1 (en) Functional food for preventing or improving osteoarthritis containing an extract of Angelica gigas Nakai
RU2248212C2 (en) Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis
US20160367719A1 (en) Fractions of extracts of helichrysum having mucohadhesive properties
Yang et al. Aucubin alleviates methotrexate‐induced enteritis in rats by inducing autophagy
US20200246411A1 (en) Anti-diarrhoeal herbal compositions
Surai et al. Silymarin and inflammation: From understanding molecular mechanisms to practical applications
CN105561302A (en) Psoriasis treating medicine containing lysozyme
US6248372B1 (en) Bioactive rice flour extract useful for treatment of haemophilus influenzae infections
Nongrum et al. Possible role of Immunonutrients in combating Covid-19 outbreak
FR3145272A1 (en) Anti-inflammatory composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21723282

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 3177105

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022567246

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022021695

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227041721

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202217070275

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021723282

Country of ref document: EP

Effective date: 20221207

ENP Entry into the national phase

Ref document number: 2021267004

Country of ref document: AU

Date of ref document: 20210507

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112022021695

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221026